rnf41 Antibody

What is RNF41 and why is it important in cellular signaling?

RNF41 (Ring Finger Protein 41), also known as Nrdp1 (Neuregulin Receptor Degradation Protein-1) or FLRF (Fetal Liver Ring Finger), is an E3 ubiquitin ligase that belongs to the family of single RING finger-containing proteins. It functions as a scaffold by coordinating ubiquitin transfer from ubiquitin-conjugating enzymes to specific substrates . RNF41 plays essential roles in several critical cellular processes, including:

• Degradation of proinflammatory cytokine receptors, adaptors, and kinases

• Inhibition of inflammatory cytokine production through suppression of MyD88 and NF-κB activation

• Promotion of anti-inflammatory macrophage polarization via ubiquitination and activation of C/EBPβ

• Regulation of type 1 cytokine receptor degradation and ectodomain shedding

Understanding RNF41 is particularly important because of its involvement in inflammatory conditions, fibrosis resolution, and oncogenic signaling pathways, making it a potential therapeutic target.

What are the key biological systems where RNF41 antibodies are most useful?

RNF41 antibodies have demonstrated particular utility in several biological systems:

• Liver disease research: RNF41 expression is downregulated in macrophages from cirrhotic livers compared to healthy livers, regardless of cirrhosis etiology (alcoholic, nonalcoholic, hepatitis C, or autoimmune) .

• Inflammatory conditions: RNF41 inhibits proinflammatory cytokine production in Toll-like receptor–triggered macrophages and confers resistance to lipopolysaccharide-induced endotoxin shock .

• Cancer research: RNF41 regulates HER3 levels and signaling, which has implications for cancer proliferation and resistance to anti-HER3 therapies .

• Cytokine signaling: RNF41 modulates JAK-STAT signaling pathways by controlling the degradation and shedding of type 1 cytokine receptors, including those for leptin, leukaemia inhibitory factor, and interleukin-6 .

For tissue samples, RNF41 antibodies have been validated for detection in human testis tissue (for Western blot) and human liver cancer tissue (for immunohistochemistry) .

How does RNF41 contribute to macrophage polarization and what experimental approaches best capture this process?

RNF41 promotes anti-inflammatory macrophage polarization through ubiquitination and activation of the transcription factor CCAAT/enhancer-binding protein β (C/EBPβ) . This polarization shift is characterized by elevated expression of CD206 (mannose receptor, an anti-inflammatory macrophage marker) .

Recommended experimental approaches:

• Phenotypic assessment: Monitor changes in macrophage morphology and CD206 expression following RNF41 overexpression or knockdown.

• Functional assays: Measure collagenase activity of macrophages using FITC-gelatin degradation assays. Anti-inflammatory macrophages with elevated RNF41 expression demonstrate increased matrix metalloproteinase (MMP) production and enhanced ability to degrade extracellular matrix proteins .

• Expression analysis: Quantify RNF41 and USP8 (a known stabilizer of RNF41 activity) expression in CD11b+ macrophages isolated from healthy versus diseased tissues .

• In vitro polarization models: When studying RNF41's role in macrophage polarization, TNF-α can be used as a CD11b promoter activator. In experimental settings, pRNF41-DGNP (plasmid-dendrimeric gold nanoparticles) combined with TNF-α demonstrates effectiveness in switching macrophage morphology and phenotype .

What are the critical parameters for studying RNF41-mediated regulation of receptor degradation versus shedding?

RNF41 affects receptor turnover in a dual manner: it blocks intracellular cathepsin-L-dependent receptor cleavage while simultaneously enhancing receptor shedding by metalloproteases of the ADAM family . To effectively study this dual regulation:

Key experimental parameters:

• Receptor compartmentalization analysis: Compare cell surface receptor levels (by flow cytometry) with total receptor expression (by Western blot) to determine changes in receptor localization.

• Soluble receptor quantification: Collect cell culture supernatants to analyze receptor shedding. For example, RNF41 expression significantly increases soluble leptin receptor (LR) levels from hLR-HA-expressing cells .

• Protease inhibitor controls: Include metalloprotease inhibitors (e.g., TAPI-1) to block receptor ectodomain shedding and distinguish between degradation and shedding effects .

• Structural domain analysis: Compare wild-type RNF41 with RING domain mutants (RNF41 ΔRING). The RING domain is crucial for RNF41's E3 ubiquitin ligase activity; ΔRING mutants act as dominant-negative inhibitors, potentiating signaling by interfering with receptor degradation .

• Receptor trafficking visualization: Use fluorescent-tagged receptors to track their movement between cellular compartments in response to RNF41 manipulation.

How can researchers effectively analyze RNF41's role in ubiquitination pathways?

Analysis of RNF41's ubiquitination activities requires careful experimental design:

• E3 ligase activity assays: Assess RNF41's ability to coordinate ubiquitin transfer from E2 enzymes to specific substrates using in vitro ubiquitination assays.

• Substrate identification: Use proteomic approaches combined with RNF41 immunoprecipitation to identify novel substrates. Known substrates include HER3, BRUCE, parkin, and type 1 cytokine receptors .

• Ubiquitination detection: Use antibodies against polyubiquitin chains to detect increased ubiquitination of target proteins following RNF41 overexpression. For instance, IgG 95 (an anti-HER3 antibody) enhanced HER3 ubiquitination through an RNF41-dependent mechanism .

• Functional genomic screening: Implement shRNA libraries targeting the ubiquitin proteasome system to identify genes that affect RNF41-dependent phenotypes. In one study, an shRNA screen revealed that down-regulation of RNF41 enhanced resistance to an anti-HER3 antibody treatment .

• Domain-specific mutants: Compare effects of wild-type RNF41 versus truncated versions lacking functional domains (particularly the N-terminal RING domain) to understand domain-specific functions .

What are the optimal protocols for using RNF41 antibodies in Western blot applications?

Based on validated protocols for RNF41 antibody (17233-1-AP), researchers should consider the following for Western blot applications:

Protocol recommendations:

Additional considerations:

• RNF41 has a calculated molecular weight of 317 amino acids (36 kDa)

• Full name: ring finger protein 41

• GenBank Accession Number: BC032637

• Gene ID (NCBI): 10193

When analyzing RNF41 expression patterns, consider comparing expression levels in different tissues or cell types, particularly in inflammatory conditions versus healthy states, as RNF41 expression is known to be downregulated in certain disease conditions .

What specialized techniques are recommended for immunohistochemical detection of RNF41 in liver tissue?

For immunohistochemical detection of RNF41 in liver tissue samples, particularly liver cancer tissues, the following protocol specifications are recommended:

IHC protocol details:

Important considerations:

• Titration of antibody concentration is recommended for each testing system to obtain optimal results

• Sample-dependent variations may exist; checking validation data is advised

• For liver fibrosis studies, comparison between healthy and fibrotic tissues is recommended, as RNF41 expression is down-regulated in CD11b+ macrophages from fibrotic liver specimens

How can researchers effectively detect RNF41-dependent changes in macrophage function?

To detect RNF41-dependent changes in macrophage function, researchers should implement multiple complementary approaches:

• Phenotypic markers: Monitor expression of anti-inflammatory macrophage markers such as CD206 (mannose receptor) following RNF41 manipulation. Flow cytometry or immunofluorescence can be used for this purpose .

• Morphological assessment: Document changes in macrophage morphology, as RNF41 expression in macrophages is associated with phenotypic transition .

• Functional assays:

  • Matrix degradation: Use FITC-gelatin degradation assays to assess collagenase activity. RAW 264.7 macrophages treated with pRNF41-DGNPs display enhanced collagen digestion, visible as a black halo around cells on FITC-gelatin–coated plates .

  • Cytokine profiling: Measure pro- and anti-inflammatory cytokine production before and after RNF41 expression modulation.

• Expression correlation: Analyze correlation between RNF41 expression and USP8 (a stabilizer of RNF41) in macrophages from different disease states .

• In vivo models: Consider CCl₄-induced chronic liver injury and fibrosis in BALB/c mice, which shows downregulation of RNF41 in CD11b+ macrophages, mirroring findings in human fibrotic specimens .

What are the common challenges in RNF41 antibody-based experiments and how can they be overcome?

Researchers working with RNF41 antibodies may encounter several challenges:

• Expression level variations: RNF41 expression can vary significantly between tissue types and disease states. For example, RNF41 mRNA expression is notably lower in macrophages from cirrhotic liver compared to healthy liver .

  • Solution: Include appropriate tissue/cell-specific positive controls and normalize expression to housekeeping genes.

• Protein degradation: As an E3 ubiquitin ligase, RNF41 regulates its own stability through auto-ubiquitination.

  • Solution: Use fresh samples, include protease inhibitors, and consider protein stabilization approaches.

• RING domain functionality: RNF41 lacking a functional RING domain acts as a dominant-negative inhibitor .

  • Solution: When studying RNF41 function, compare effects of wild-type versus RING domain mutants to distinguish between ligase-dependent and independent functions.

• Antibody specificity: Ensure specificity for RNF41 versus related RING finger proteins.

  • Solution: Validate antibody specificity using RNF41 knockdown/knockout controls, particularly when studying tissues where related proteins may be expressed.

• Subcellular localization: RNF41 may localize differently depending on cellular context.

  • Solution: Combine multiple detection methods (immunofluorescence, subcellular fractionation followed by Western blot) to confirm localization patterns.

How can researchers distinguish between direct and indirect effects of RNF41 in experimental systems?

Distinguishing direct from indirect effects of RNF41 requires careful experimental design:

• Domain mutant analysis: Compare effects of wild-type RNF41 versus catalytically inactive RING domain mutants. For example, RNF41 expression increases soluble LR levels, whereas RNF41 ΔRING has no effect, indicating a RING domain-dependent mechanism .

• Substrate interaction validation: Use co-immunoprecipitation, proximity ligation assays, or MAPPIT (Mammalian Protein-Protein Interaction Trap) to confirm direct interaction between RNF41 and putative substrates. The MAPPIT approach has successfully demonstrated RNF41 interaction with JAK2-associated cytokine receptor complexes .

• Temporal analysis: Establish the kinetics of RNF41-mediated effects through time-course experiments. For example, the incorporation of pRNF41-DGNPs in activated macrophages increases over time, with differential patterns in the presence of activating factors like TNF-α .

• Rescue experiments: In RNF41 knockdown systems, reintroduce either wild-type or mutant RNF41 to determine which domains are necessary for specific phenotypes. This approach revealed that down-regulation of RNF41 enhanced resistance to anti-HER3 antibody treatment .

• Pathway inhibitors: Use specific inhibitors of downstream pathways to determine whether RNF41 effects require these pathways. For instance, metalloprotease inhibitor TAPI-1 can block RNF41-enhanced receptor shedding, confirming the involvement of metalloproteases of the ADAM family in this process .

What are the key considerations when designing RNF41 knockdown or overexpression studies?

When manipulating RNF41 expression levels, researchers should consider:

• Expression system selection:

  • For overexpression: Plasmid-based systems with appropriate promoters (e.g., CD11b promoter for macrophage-specific expression) have been successfully employed .

  • For knockdown: shRNA approaches targeting RNF41 have been effective in identifying its role in resistance to targeted therapies .

• Delivery methods:

  • Conventional transfection for in vitro studies

  • Plasmid-dendrimeric gold nanoparticles (pRNF41-DGNPs) have shown effectiveness for selective delivery to macrophages, particularly those in inflammatory states .

• Expression confirmation:

  • Verify RNF41 expression changes at both mRNA (qPCR) and protein (Western blot) levels

  • Include reporter genes (e.g., EGFP) to track successful transfection

• Functional readouts:

  • For macrophage studies: phagocytic activity, cytokine production, surface marker expression

  • For receptor regulation studies: measure both membrane-bound and soluble receptor levels

  • For signaling studies: assess phosphorylation of downstream targets (e.g., pAKT levels in HER3 signaling)

• Physiological relevance:

  • Consider the endogenous expression levels of RNF41 in your cell type of interest

  • Validate findings in multiple cell lines or primary cells

  • When possible, confirm in vivo using appropriate animal models, such as the CCl₄-induced chronic liver injury model used to study RNF41 in fibrosis

What are emerging applications of RNF41 antibodies in therapeutic development research?

RNF41 antibodies are becoming increasingly important tools for exploring potential therapeutic interventions:

• Fibrosis resolution: RNF41 orchestrates macrophage-driven fibrosis resolution, suggesting that strategies to enhance RNF41 expression in macrophages could have therapeutic potential for fibrotic diseases. Antibodies are essential for tracking RNF41 expression in both experimental models and patient samples .

• Cancer therapy resistance: RNF41 is implicated in the mechanism of action for anti-HER3 antibodies, with down-regulation of RNF41 potentially serving as a mechanism for acquired resistance. RNF41 antibodies can help monitor this resistance mechanism in tumor samples .

• Inflammatory conditions: Given RNF41's role in suppressing proinflammatory cytokine production and promoting anti-inflammatory macrophage polarization, antibodies against RNF41 are valuable for studying its expression in various inflammatory conditions .

• Cytokine signaling modulation: RNF41's dual role in regulating receptor degradation and shedding makes it a potential target for modulating cytokine signaling. Antibodies can help assess how therapeutic interventions affect RNF41 levels and function .

• Biomarker development: RNF41 expression patterns in macrophages could potentially serve as biomarkers for disease progression or treatment response, particularly in fibrotic diseases where RNF41 expression is altered .

How can multi-omics approaches enhance understanding of RNF41 biology?

Integrating multiple omics approaches can provide comprehensive insights into RNF41 function:

• Proteomics:

  • Identify the complete spectrum of RNF41 substrates through ubiquitinome analysis

  • Map RNF41 interaction networks via proximity labeling approaches

  • Characterize post-translational modifications of RNF41 that regulate its activity

• Transcriptomics:

  • Profile gene expression changes in response to RNF41 manipulation to identify downstream transcriptional consequences

  • Analyze RNF41 expression across different tissues and disease states using public databases

• Genomics:

  • Explore genetic variations in RNF41 that might be associated with disease susceptibility

  • Use CRISPR-based screens to identify synthetic lethal interactions with RNF41

• Single-cell analysis:

  • Characterize RNF41 expression and function in heterogeneous cell populations, particularly in complex tissues like liver where multiple cell types contribute to disease pathology

• Systems biology:

  • Develop computational models of RNF41's role in ubiquitination networks

  • Integrate multi-omics data to predict the consequences of therapeutic RNF41 modulation

Such multi-omics approaches could reveal new aspects of RNF41 biology beyond its currently understood roles in receptor degradation, macrophage polarization, and ubiquitination pathways.